These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 39002523)
1. TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches. Hu W; Li D; Yang Y; Zheng Y; Zeng J; Sai K Int Immunopharmacol; 2024 Sep; 139():112665. PubMed ID: 39002523 [TBL] [Abstract][Full Text] [Related]
2. Identification of DNA methylation-regulated WEE1 with potential implications in prognosis and immunotherapy for low-grade glioma. Zhong WJ; Zhang LZ; Yue F; Yuan L; Zhang Q; Li X; Lin L Cancer Biomark; 2024; 40(3-4):297-317. PubMed ID: 39213054 [TBL] [Abstract][Full Text] [Related]
3. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924 [TBL] [Abstract][Full Text] [Related]
4. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787 [TBL] [Abstract][Full Text] [Related]
5. High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients. An W; Ren C; Yuan L; Qiu Z; Wang P; Cheng Y; He Z; Han X; Li S; An Y Front Immunol; 2024; 15():1411072. PubMed ID: 39211050 [TBL] [Abstract][Full Text] [Related]
6. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
7. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X Front Immunol; 2022; 13():899710. PubMed ID: 35677036 [TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration. M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625 [TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma. Qu J; Zhao Q; Yang L; Ping Y; Zhang K; Lei Q; Liu F; Zhang Y Int Immunopharmacol; 2021 Jul; 96():107616. PubMed ID: 34162127 [TBL] [Abstract][Full Text] [Related]
10. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CD68 and kallikrein 6 in human glioma. Strojnik T; Kavalar R; Zajc I; Diamandis EP; Oikonomopoulou K; Lah TT Anticancer Res; 2009 Aug; 29(8):3269-79. PubMed ID: 19661345 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778 [TBL] [Abstract][Full Text] [Related]
13. Spatial interaction and functional status of CD68 Liu X; Zhang Z; Yuan J; Yu J; Chen D Front Immunol; 2024; 15():1396719. PubMed ID: 38799432 [TBL] [Abstract][Full Text] [Related]
14. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma. Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612 [TBL] [Abstract][Full Text] [Related]
15. Correlation of immune phenotype with IDH mutation in diffuse glioma. Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337 [TBL] [Abstract][Full Text] [Related]
16. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas. Li J; Zhang Y; Qu Z; Ding R; Yin X Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373 [TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
18. Integrated bioinformatics analysis and experimental validation reveal the relationship between ALOX5AP and the prognosis and immune microenvironment in glioma. Song P; Deng H; Liu Y; Zhang M BMC Med Genomics; 2024 Aug; 17(1):218. PubMed ID: 39169376 [TBL] [Abstract][Full Text] [Related]
19. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs). Zhang Z; Xiao Y; Zhao S; Liu J; Zeng J; Xiao F; Liao B; Shan X; Zhu H; Guo H J Transl Med; 2024 Sep; 22(1):833. PubMed ID: 39256832 [TBL] [Abstract][Full Text] [Related]
20. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]